Free Trial

Coherus BioSciences (CHRS) Stock Forecast & Price Target

Coherus BioSciences logo
$0.76 +0.02 (+2.12%)
(As of 09:15 AM ET)

Coherus BioSciences - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
1
Buy
3

Based on 4 Wall Street analysts who have issued ratings for Coherus BioSciences in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 4 analysts, 1 has given a hold rating, and 3 have given a buy rating for CHRS.

Consensus Price Target

$6.13
706.13% Upside
According to the 4 analysts' twelve-month price targets for Coherus BioSciences, the average price target is $6.13. The highest price target for CHRS is $12.00, while the lowest price target for CHRS is $1.50. The average price target represents a forecasted upside of 706.13% from the current price of $0.76.

CHRS Analyst Ratings Over Time

TypeCurrent Forecast
11/19/23 to 11/18/24
1 Month Ago
10/20/23 to 10/19/24
3 Months Ago
8/21/23 to 8/20/24
1 Year Ago
11/19/22 to 11/19/23
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
3 Buy rating(s)
4 Buy rating(s)
4 Buy rating(s)
6 Buy rating(s)
Hold
1 Hold rating(s)
2 Hold rating(s)
2 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$6.13$7.10$6.92$12.78
Forecasted Upside706.13% Upside704.17% Upside453.33% Upside499.90% Upside
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy

CHRS Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

CHRS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Coherus BioSciences Stock vs. The Competition

TypeCoherus BioSciencesMedical CompaniesS&P 500
Consensus Rating Score
2.75
2.80
2.50
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside723.25% Upside28,497.56% Upside9.87% Upside
News Sentiment Rating
Positive News

See Recent CHRS News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
11/8/2024Robert W. Baird
2 of 5 stars
 Lower TargetOutperform ➝ Outperform$8.00 ➝ $4.00+387.80%
11/7/2024HC Wainwright
2 of 5 stars
 Reiterated RatingBuy ➝ Buy$12.00 ➝ $12.00+1,557.90%
8/16/2024UBS Group
4 of 5 stars
A. Verma
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral$4.00 ➝ $1.50-3.23%
5/13/2024Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$8.00 ➝ $7.00+258.97%
11/8/2023Maxim Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold
10/23/2023Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$8.00 ➝ $7.00+112.12%
Pro trader:: Wall Street Algorithms can be predictably profitable (Ad)

Patterns that often precede a bullish move to the upside. In fact, by following these patterns our top trader has found 96 winning opportunities out of the 129 he’s targeted… And for the first time on a large scale, he’s going to show you how to find these algorithmic patterns… As you’ll see right here, you can find them with just one single indicator and your two eyes… This week, he’s hosting a free class where we’ll show you what this pattern is and what causes it to form… Of course, he could never promise a future return or against losses

10/12/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$7.00 ➝ $6.00+59.57%
7/24/2023Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$12.00+179.72%
3/14/2023Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$21.00 ➝ $23.00+261.07%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 09:32 AM ET.


CHRS Forecast - Frequently Asked Questions

According to the research reports of 4 Wall Street equities research analysts, the average twelve-month stock price forecast for Coherus BioSciences is $6.13, with a high forecast of $12.00 and a low forecast of $1.50.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Coherus BioSciences in the last year. There is currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" CHRS shares.

According to analysts, Coherus BioSciences's stock has a predicted upside of 706.13% based on their 12-month stock forecasts.

Coherus BioSciences has been rated by research analysts at HC Wainwright, and Robert W. Baird in the past 90 days.

Analysts like Coherus BioSciences less than other "medical" companies. The consensus rating score for Coherus BioSciences is 2.75 while the average consensus rating score for "medical" companies is 2.80. Learn more on how CHRS compares to other companies.


This page (NASDAQ:CHRS) was last updated on 11/18/2024 by MarketBeat.com Staff
From Our Partners